## Core Concept
Bleomycin is a chemotherapeutic agent used in the treatment of various cancers. It works by inducing DNA strand breaks, thereby inhibiting DNA synthesis and cell division. The toxicity of bleomycin is particularly notable in certain types of cells.

## Why the Correct Answer is Right
The correct answer, **C. Pneumocytes and skin cells**, is right because bleomycin primarily causes toxicity in type II pneumocytes in the lungs and skin cells. Type II pneumocytes are crucial for producing surfactant, which reduces surface tension in the lungs. Damage to these cells can lead to pulmonary fibrosis, a well-known side effect of bleomycin. Skin cells are also commonly affected, leading to dermatitis and skin reactions.

## Why Each Wrong Option is Incorrect
- **Option A:** This option is incorrect because while bleomycin does affect rapidly dividing cells, it is not specific to bone marrow cells. Its toxicity profile is different from that of typical bone marrow-suppressing agents.
- **Option B:** This option is incorrect because bleomycin's mechanism does not specifically target gastrointestinal mucosa as its primary site of toxicity.
- **Option D:** This option is incorrect because, although bleomycin can affect many types of cells due to its mechanism of action on DNA, its toxicity is particularly noted in pneumocytes and skin cells, not specifically in muscle cells.

## Clinical Pearl / High-Yield Fact
A key point to remember is that **bleomycin-induced pulmonary toxicity** is dose-dependent and can be fatal. Monitoring lung function tests, especially DLCO (diffusing capacity of the lungs for carbon monoxide), is crucial in patients receiving bleomycin. A classic clinical correlation is that patients on bleomycin should avoid high concentrations of oxygen to minimize the risk of pulmonary toxicity.

## Correct Answer: C. Pneumocytes and skin cells